CG ONCOLOGY, INC.

Press Releases CG Oncology, Inc.

Equities

CGON

US1569441009

Real-time Estimate Cboe BZX Other stock markets 16:15:10 23/05/2024 BST			5-day change	1st Jan Change
31.6 ^USD	+2.58%		+0.29%	0.00%

05-14	Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target	MT
05-09	CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates	05-09	AQ
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	05-06	AQ
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	05-03	AQ
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024	04-26	AQ
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024	04-24	AQ
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting	03-28	AQ
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer	02-27	AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares	01-31	AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	01-30	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer